When investing, it is important to consider companies and ventures that address common problems. Unfortunately, heart disease is an extremely common problem, as in the U.S. it kills one in three women and one in four men each year. In the developed world as a whole, it kills one in three people. Because there are so many variables related to heart disease – diet, genetics, exercise, other health factors – it is very unlikely that there will ever be a cure to fully eliminate heart disease.
However, there will be an ongoing need for innovative treatments to cure various ailments – valve replacements, weakened muscle tissue, less advanced heart failure and more. The average cost of a valve replacement surgery in the U.S. is about $164,238, excluding the doctor fee, for a valve that may only last 10 or 15 years.
Because of a lack of supply and an increasing demand, there is a seemingly unfathomable market opportunity for new treatments like biological components and transplantable organs. One heart transplant costs about $500,000 in the U.S., and about 3,800 are performed each year. This means heart transplants generate almost $2 billion annually in the U.S. alone based on current procedures. Just imagine how incredible the market opportunity would be if everyone who actually needed a heart transplant could finally actually get one! With heart disease likely here to stay, this is a huge market primed for innovation.
For all of the reasons mentioned above, BIOLIFE4D is raising funds to develop transplantable human hearts and incremental solutions like heart valves. We look not only to save lives by addressing the supply and demand problem, but also by providing a solution to organ rejection, the process in which transplant recipients’ bodies reject the new organs as foreign objects. By bioprinting organs using patients’ own cells, their bodies will recognize and accept the new organs as their own. These solutions not only have the potential to change global healthcare, but also to reward investors like yourself.